CatalYm Doses First Patient in Phase 2/3 Trial of Visugromab for Cancer Cachexia

Key Takeaways

• CatalYm has dosed the first patient in its Phase 2/3 VINCIT trial evaluating visugromab for cancer-associated cachexia
• The global study will enroll approximately 518 patients with cachexia from various advanced cancers including non-small cell lung cancer
• Visugromab targets GDF-15, a protein linked to muscle wasting and weight loss in cancer patients

---

CatalYm announced a significant milestone in cancer cachexia treatment with the first patient dosing in its Phase 2/3 VINCIT trial (Visugromab IN Cachexia International Trial, NCT07112196). The Munich and San Francisco-based biotechnology company is evaluating visugromab, its lead anti-GDF-15 antibody, as a potential treatment for cancer-associated cachexia.

Trial Design and Patient Population

The randomized, double-blind, placebo-controlled Phase 2/3 trial aims to enroll approximately 518 patients suffering from cachexia associated with various advanced cancers, including non-small cell lung cancer. Cancer cachexia affects up to 80% of patients with advanced cancer and is characterized by severe muscle wasting, weight loss, and fatigue that significantly impacts quality of life and survival outcomes.

IntelligenceRegulatory Impact▾

NMPA, PMDA, and TGA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Mechanism of Action

Visugromab works by targeting GDF-15 (Growth Differentiation Factor-15), a protein that becomes elevated in cancer patients and contributes to appetite loss, muscle wasting, and metabolic dysfunction. By blocking GDF-15, visugromab aims to preserve muscle mass and improve nutritional status in cancer patients.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Unmet Need

Currently, there are limited effective treatments for cancer cachexia, representing a significant unmet medical need. The condition not only reduces patients’ ability to tolerate cancer treatments but also independently contributes to mortality. Success in this Phase 2/3 trial could position visugromab as a first-in-class therapy addressing this critical gap in cancer care.

The global nature of the VINCIT trial reflects the worldwide prevalence of cancer cachexia and CatalYm’s commitment to developing a treatment that could benefit cancer patients internationally. The company’s advancement into late-stage clinical development represents a crucial step toward potentially bringing the first targeted therapy for cancer cachexia to market.

---

Frequently Asked Questions

What is cancer cachexia and how does visugromab help?

Cancer cachexia is severe muscle wasting and weight loss affecting up to 80% of advanced cancer patients. Visugromab blocks GDF-15, a protein that causes appetite loss and muscle breakdown in cancer patients.

When will visugromab be available for patients?

Visugromab is currently in Phase 2/3 trials with 518 patients. If successful, the drug could potentially reach market in 2-3 years, pending regulatory approval.

How does visugromab compare to existing cachexia treatments?

There are currently no approved targeted therapies for cancer cachexia. Visugromab would be first-in-class as an anti-GDF-15 antibody specifically designed to address the underlying mechanisms of cancer-related muscle wasting.

Related coverage

• ASCO26: Revolution's Daraxonrasib Phase III Data Reshapes Pancreatic Cancer Odds
• Orion Pharma's ODM-212 Shows Favorable Safety in Phase 1/2 TEADES Trial for Advanced Solid Tumours
• Risen Pharma Initiates Phase 2 Trial for RP902 in Alzheimer's